Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Guinea Bissau Health Bulletin.
Press releases published on October 21, 2025
Glucose Health, Inc. (OTC: GLUC) Announces New Management Appointments and Strategic Outlook
BENTONVILLE, Ark., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) today announced the appointment of Mark Schaftlein as Chief Executive Officer and member of the Board of Directors, effective October 20, 2025. The Company also announced …
Simcha Therapeutics Presents Preclinical Data Demonstrating Potential for Decoy-Resistant IL-18 to Enhance Efficacy of Bi-specific T-cell Engagers
SOUTH SAN FRANCISCO, Calif., and NEW HAVEN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments for cancer, today announced the presentation of …
Konica Minolta Healthcare Receives Innovative Technology Designation from Vizient for Dynamic Digital Radiography
WAYNE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., is pleased to announce its Dynamic Digital Radiography (DDR) technology has received an Innovative Technology designation from Vizient®, the nation’s largest …
NIH Grant Awarded to Further Research of Novel Chemical Pathway to Reverse MCI
SAN FRANCISCO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The NIH has awarded a new grant to Posit Science, the maker of the online BrainHQ brain exercises, to advance research, which showed in a neuro-imaging study published last week, that their brain exercises …
Solenic Medical Announces Successful Use of Its AMF Technology Under FDA Compassionate Use Authorization
DALLAS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Solenic Medical, a medical device company developing an innovative treatment for orthopedic implant infections, today announced the successful, FDA-authorized compassionate use of its investigational Alternating …
PetVivo Holdings, Inc. Addresses Veterinary Industry's GEN Z Problem With Breakthrough AI License Agreement
MINNEAPOLIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., an emerging biomedical device company focused on the commercialization of …
MediBeacon receives regulatory approval to sell the Transdermal GFR System in China
MediBeacon® Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function The TGFR will be available for sale in China before the end of the year ST. LOUIS, Oct. …
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and…
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone’s clinical development and NDA resubmission. Further $40 million …
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
AskBio Announces Publication in Nature Medicine of 12-month data from Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure
Research Triangle Park, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- First-in-human trial of investigational gene therapy AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure …
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC) Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University have now …
Vertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative Diseases
Formerly Axial Therapeutics, Vertero is rapidly advancing a novel approach to address peripheral drivers of challenging neurodegenerative diseases Lead candidate VT-5006 is a first-in-class small molecule designed to precisely engage a validated target in …
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 ( …
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage …
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation in the Guggenheim Securities 2nd …
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that it …
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025
SHANGHAI and WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical …
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical …
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced …